Abstract
Opiates are powerful drugs to treat severe pain, and act via mu opioid receptors distributed throughout the nervous system. Their clinical use is hampered by centrally-mediated adverse effects, including nausea or respiratory depression. Here we used a genetic approach to investigate the potential of peripheral mu opioid receptors as targets for pain treatment. We generated conditional knockout (cKO) mice in which mu opioid receptors are deleted specifically in primary afferent Nav1.8-positive neurons. Mutant animals were compared to controls for acute nociception, inflammatory pain, opiate-induced analgesia and constipation. There was a 76% decrease of mu receptor-positive neurons and a 60% reduction of mu-receptor mRNA in dorsal root ganglia of cKO mice. Mutant mice showed normal responses to heat, mechanical, visceral and chemical stimuli, as well as unchanged morphine antinociception and tolerance to antinociception in models of acute pain. Inflammatory pain developed similarly in cKO and controls mice after Complete Freund’s Adjuvant. In the inflammation model, however, opiate-induced (morphine, fentanyl and loperamide) analgesia was reduced in mutant mice as compared to controls, and abolished at low doses. Morphine-induced constipation remained intact in cKO mice. We therefore genetically demonstrate for the first time that mu opioid receptors partly mediate opiate analgesia at the level of Nav1.8-positive sensory neurons. In our study, this mechanism operates under conditions of inflammatory pain, but not nociception. Previous pharmacology suggests that peripheral opiates may be clinically useful, and our data further demonstrate that Nav1.8 neuron-associated mu opioid receptors are feasible targets to alleviate some forms of persistent pain.
Highlights
Opiates such as morphine, acting at mu opioid receptors, represent the most widely used drugs for the management of severe pain
The present study shows that deletion of mu receptors in peripheral Nav1.8 sensory neurons decreases mu opiates-induced analgesia in inflammatory pain situation but not in acute nociception assays
In order to test this hypothesis, we evaluated the number of mu receptor-expressing neurons in the DRGs of both mu-conditional knockout (cKO) and mufl mice 48h after Complete Freund Adjuvant (CFA), using In situ hybridization (ISH) as above (Figure 1)
Summary
Opiates such as morphine, acting at mu opioid receptors, represent the most widely used drugs for the management of severe pain. Opioid receptors have been shown to inhibit pain transmission in ascending pain pathways including primary afferent fibers [4]. Combined pharmacology and knockout approaches have confirmed that the molecular targets for the analgesic and side effects of the clinically used opiates are the mu receptors, encoded by the Oprm gene [9]. Drug treatments targeting opioid receptors outside the central nervous system are considered as a potential therapeutic strategy to limit centrally mediated side effects, and first trials using peripherally acting mu agonists at preclinical and clinical levels have been promising [4]. The significance of peripheral mu receptors in opiate-induced analgesia has not yet been investigated by gene knockout approaches
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have